Moleculin Biotech Inc. (MBRX)
1.83
-0.08 (-4.19%)
At close: Jan 15, 2025, 3:59 PM
1.85
1.09%
After-hours Jan 15, 2025, 04:09 PM EST
undefined% (undefined)
| Bid | 1.78 |
| Market Cap | 5.84M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -12.04 |
| PE Ratio (ttm) | -0.15 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2 |
| Volume | 33,751 |
| Avg. Volume (20D) | 54,322 |
| Open | 1.90 |
| Previous Close | 1.91 |
| Day's Range | 1.76 - 1.95 |
| 52-Week Range | 0.40 - 6.24 |
| Beta | undefined |
About MBRX
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial fo...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 2, 2016
Employees 18
Stock Exchange NASDAQ
Ticker Symbol MBRX
Website https://www.moleculin.com
Analyst Forecast
According to 2 analyst ratings, the average rating for MBRX stock is "Buy." The 12-month stock price forecast is $24, which is an increase of 1211.48% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
1 month ago ·
Source
+14.72%
Moleculin Biotech shares are trading higher after ...
Unlock content with
Pro Subscription
2 months ago ·
Source
+23.11%
Moleculin Biotech shares are trading higher after the company announced it amended the clinical trial protocol with the FDA for its Phase 3 pivotal trial protocol evaluating Annamycin in combination with Cytarabine for the treatment of AML patients who are refractory to or relapsed after induction therapy.
